Arizona State Retirement System boosted its position in shares of Mylan (NASDAQ:MYL) by 4.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 201,944 shares of the company’s stock after acquiring an additional 7,742 shares during the period. Arizona State Retirement System’s holdings in Mylan were worth $8,544,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Meeder Asset Management Inc. boosted its holdings in shares of Mylan by 76.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 3,393 shares of the company’s stock worth $106,000 after acquiring an additional 1,475 shares in the last quarter. BT Investment Management Ltd bought a new position in Mylan in the 3rd quarter worth approximately $142,000. Rational Advisors LLC bought a new position in Mylan in the 4th quarter worth approximately $190,000. First Personal Financial Services raised its position in Mylan by 77.1% in the 4th quarter. First Personal Financial Services now owns 4,839 shares of the company’s stock worth $205,000 after purchasing an additional 2,106 shares during the last quarter. Finally, Mycio Wealth Partners LLC bought a new stake in shares of Mylan during the 4th quarter valued at $212,000. Hedge funds and other institutional investors own 84.82% of the company’s stock.
Several brokerages have commented on MYL. Goldman Sachs Group upped their target price on shares of Mylan from $46.00 to $52.00 and gave the company a “buy” rating in a research report on Thursday, January 11th. Citigroup restated a “buy” rating and issued a $58.00 price objective (up previously from $48.00) on shares of Mylan in a research report on Thursday, January 4th. Leerink Swann initiated coverage on shares of Mylan in a research note on Tuesday, January 2nd. They issued a “market perform” rating and a $44.00 target price for the company. TheStreet upgraded shares of Mylan from a “c” rating to a “b-” rating in a research note on Wednesday, January 17th. Finally, BidaskClub downgraded shares of Mylan from a “buy” rating to a “hold” rating in a research note on Saturday, February 3rd. Nine equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Mylan presently has a consensus rating of “Buy” and a consensus price target of $45.92.
Mylan (NASDAQ:MYL) last released its earnings results on Wednesday, February 28th. The company reported $1.43 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.41 by $0.02. Mylan had a net margin of 5.84% and a return on equity of 19.14%. The firm had revenue of $3.24 billion for the quarter, compared to analysts’ expectations of $3.29 billion. During the same period in the previous year, the company earned $1.57 earnings per share. The company’s quarterly revenue was down .9% on a year-over-year basis. equities analysts predict that Mylan will post 5.38 EPS for the current fiscal year.
In other news, insider Paul Campbell sold 7,030 shares of the company’s stock in a transaction on Tuesday, March 6th. The shares were sold at an average price of $44.01, for a total value of $309,390.30. Following the completion of the sale, the insider now owns 17,054 shares of the company’s stock, valued at approximately $750,546.54. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Robert J. Coury sold 50,000 shares of the stock in a transaction on Tuesday, March 6th. The shares were sold at an average price of $43.41, for a total transaction of $2,170,500.00. The disclosure for this sale can be found here. Insiders have sold a total of 344,287 shares of company stock worth $14,409,960 in the last ninety days. 0.69% of the stock is currently owned by insiders.
Mylan Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.